Details of Disease

General Information of Disease (ID: DIS1MM9J)

Disease Name Chronic graft versus host disease
Synonyms chronic GVHD; graft versus host disease, chronic; GVHD, chronic
Definition
Chronic graft versus host disease (GVHD) is a complication that can occur after a stem cell or bone marrow transplant in which the newly transplanted donor cells attack the transplant recipient's body. Symptoms may include skin rash, mouth sores, dry eyes, liver inflammation, development of scar tissue in the skin and joints, and damage to the lungs. The exact cause of chronic GVHD is unknown.It likely results from a complex immune-mediated interaction between the donor and recipient cells.Chronic GVHD is treated with prednisone or other similar anti-inflammatory or immunosuppressive medications.
Disease Hierarchy
DIS0QADF: Graft-versus-host disease
DIS1MM9J: Chronic graft versus host disease
Disease Identifiers
MONDO ID
MONDO_0020547
UMLS CUI
C0867389
MedGen ID
167851
Orphanet ID
99921
SNOMED CT ID
402356004

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)
This Disease is Treated as An Indication in 3 Approved Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Methylprednisolone DM4BDON Approved Small molecular drug [1]
Panobinostat DM58WKG Approved Small molecular drug [2]
Prednisolone DMQ8FR2 Approved Small molecular drug [3]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)
This Disease Is Related to 20 DTT Molecule(s)
Gene Name DTT ID Evidence Level Mode of Inheritance REF
BCL6 TTC9YX5 Limited Biomarker [4]
CR2 TT0HUN7 Limited Biomarker [5]
FOSL2 TT689IR Limited Biomarker [6]
ICOS TTE5VP6 Limited Biomarker [7]
LY9 TTZCL1U Limited Biomarker [8]
NPR2 TTNB7IF Limited Biomarker [8]
TNFSF13B TTWMIDN Limited Altered Expression [9]
APOA4 TTNC3WS moderate Biomarker [10]
C5AR1 TTHXFA1 Strong Altered Expression [11]
CD1A TTBGTFN Strong Biomarker [12]
CD22 TTM6QSK Strong Altered Expression [5]
FOXP3 TT1X3QF Strong Biomarker [12]
IL7R TTAWI51 Strong Genetic Variation [13]
IMPDH1 TT3GRLK Strong Genetic Variation [14]
KLRC1 TTC4IMS Strong Genetic Variation [15]
LTBR TTFO0PM Strong Biomarker [16]
MADCAM1 TTBD6I7 Strong Genetic Variation [17]
MS4A1 TTUE541 Strong Biomarker [18]
SELL TT2IYXF Strong Altered Expression [19]
SERPINH1 TTPSWQG Strong Biomarker [20]
------------------------------------------------------------------------------------
⏷ Show the Full List of 20 DTT(s)
This Disease Is Related to 2 DME Molecule(s)
Gene Name DME ID Evidence Level Mode of Inheritance REF
LPO DEHX1DZ Strong Biomarker [21]
NDUFS7 DEIW03B Strong Biomarker [22]
------------------------------------------------------------------------------------
This Disease Is Related to 29 DOT Molecule(s)
Gene Name DOT ID Evidence Level Mode of Inheritance REF
ACACA OT5CQPZY Limited Biomarker [23]
HLA-C OTV38BUJ Limited Biomarker [24]
HLA-DPB1 OTW8JHU2 Limited Biomarker [25]
KLRC2 OTT4N86S Limited Biomarker [15]
TBCE OTGBSTKS Limited Biomarker [26]
ANK3 OTJ3IRBP moderate Biomarker [27]
ARHGAP45 OTL86FEQ moderate Biomarker [28]
ATG10 OTVRPC5X moderate Genetic Variation [29]
DLAT OT9LBJVN moderate Biomarker [30]
HSPA1L OTC2V1K6 moderate Biomarker [31]
IFI44 OTOKSZVA moderate Biomarker [27]
IFIT1 OTXOQDSG moderate Biomarker [27]
IFIT3 OTPGHZB9 moderate Biomarker [27]
IL26 OT2WYCW4 moderate Biomarker [32]
KLRD1 OTMYLOV4 moderate Biomarker [33]
NLN OTFRITPU moderate Biomarker [34]
OPN4 OT1LZ7TS moderate Biomarker [34]
TSSK1B OTRATM7R moderate Biomarker [35]
ADSL OTSNJALL Strong Biomarker [36]
AP5M1 OTDLWEBL Strong Biomarker [37]
CRKL OTOYSD1R Strong Biomarker [38]
FCRL3 OTIFXFWL Strong Biomarker [39]
FCRL4 OT3DVTRV Strong Altered Expression [5]
HLA-E OTX1CTFB Strong Genetic Variation [40]
KIR2DS3 OT3PSLDL Strong Biomarker [41]
MICA OTPEIEAR Strong Genetic Variation [42]
NRM OTK7F9XZ Strong Biomarker [43]
PI3 OT47MTC3 Strong Biomarker [9]
PRRX1 OTTZK5G8 Strong Biomarker [44]
------------------------------------------------------------------------------------
⏷ Show the Full List of 29 DOT(s)

References

1 Methylprednisolone FDA Label
2 Panobinostat FDA Label
3 Prednisolone FDA Label
4 Small-molecule BCL6 inhibitor effectively treats mice with nonsclerodermatous chronic graft-versus-host disease.Blood. 2019 Jan 3;133(1):94-99. doi: 10.1182/blood-2018-03-839993. Epub 2018 Oct 2.
5 Evidence for B Cell Exhaustion in Chronic Graft-versus-Host Disease.Front Immunol. 2018 Jan 12;8:1937. doi: 10.3389/fimmu.2017.01937. eCollection 2017.
6 T-cell costimulation blockade is effective in experimental digestive and lung tissue fibrosis.Arthritis Res Ther. 2018 Aug 29;20(1):197. doi: 10.1186/s13075-018-1694-9.
7 Anti-Inducible Costimulator Monoclonal Antibody Treatment of Canine Chronic Graft-versus-Host Disease.Biol Blood Marrow Transplant. 2018 Jan;24(1):50-54. doi: 10.1016/j.bbmt.2017.09.010. Epub 2017 Sep 25.
8 The Checkpoint Regulator SLAMF3 Preferentially Prevents Expansion of Auto-Reactive B Cells Generated by Graft-vs.-Host Disease.Front Immunol. 2019 Apr 17;10:831. doi: 10.3389/fimmu.2019.00831. eCollection 2019.
9 B-cell activating factor (BAFF) plasma level at the time of chronic GvHD diagnosis is a potential predictor of non-relapse mortality.Bone Marrow Transplant. 2017 Jul;52(7):1010-1015. doi: 10.1038/bmt.2017.73. Epub 2017 May 8.
10 Serum proteomic profiling and haptoglobin polymorphisms in patients with GVHD after allogeneic hematopoietic cell transplantation.J Hematol Oncol. 2009 Apr 20;2:17. doi: 10.1186/1756-8722-2-17.
11 Emerging role of C5a/C5aR IL-17A axis in cGVHD.Am J Transl Res. 2018 Jul 15;10(7):2148-2157. eCollection 2018.
12 Immunohistopathological characterization and the impact of topical immunomodulatory therapy in oral chronic graft-versus-host disease: A pilot study.Oral Dis. 2018 May;24(4):580-590. doi: 10.1111/odi.12813. Epub 2018 Mar 13.
13 Donor Genotype in the Interleukin-7 Receptor -Chain Predicts Risk of Graft-versus-Host Disease and Cytomegalovirus Infection after Allogeneic Hematopoietic Stem Cell Transplantation.Front Immunol. 2018 Feb 2;9:109. doi: 10.3389/fimmu.2018.00109. eCollection 2018.
14 Inosine Monophosphate Dehydrogenase Pharmacogenetics in Hematopoietic Cell Transplantation Patients.Biol Blood Marrow Transplant. 2018 Sep;24(9):1802-1807. doi: 10.1016/j.bbmt.2018.04.006. Epub 2018 Apr 12.
15 Alterations in NKG2A and NKG2C Subsets of Natural Killer Cells Following Epstein-Barr Virus Reactivation in CTLA4Ig-based Haploidentical Transplantation Is Associated With Increased Chronic Graft-Versus-Host Disease.Transplantation. 2020 Jan;104(1):e23-e30. doi: 10.1097/TP.0000000000002941.
16 Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans.Blood. 2012 Feb 9;119(6):1570-80. doi: 10.1182/blood-2011-07-364414. Epub 2011 Nov 9.
17 Possible impact of MADCAM1 gene single nucleotide polymorphisms to the outcome of allogeneic hematopoietic stem cell transplantation.Hum Immunol. 2009 Jun;70(6):457-60. doi: 10.1016/j.humimm.2009.03.008. Epub 2009 Mar 12.
18 B cells in chronic graft-versus-host disease.Hum Immunol. 2019 Jun;80(6):393-399. doi: 10.1016/j.humimm.2019.03.003. Epub 2019 Mar 5.
19 Shaping of CD56(bri) Natural Killer Cells in Patients With Steroid-Refractory/Resistant Acute Graft-vs.-Host Disease via Extracorporeal Photopheresis.Front Immunol. 2019 Mar 20;10:547. doi: 10.3389/fimmu.2019.00547. eCollection 2019.
20 Ocular instillation of vitamin A-coupled liposomes containing HSP47 siRNA ameliorates dry eye syndrome in chronic GVHD.Blood Adv. 2019 Apr 9;3(7):1003-1010. doi: 10.1182/bloodadvances.2018028431.
21 Quantitative salivary proteomic differences in oral chronic graft-versus-host disease.J Clin Immunol. 2012 Dec;32(6):1390-9. doi: 10.1007/s10875-012-9738-4. Epub 2012 Jul 18.
22 Transplant results in adults with Fanconi anaemia.Br J Haematol. 2018 Jan;180(1):100-109. doi: 10.1111/bjh.15006. Epub 2017 Nov 2.
23 Minor histocompatibility antigens as determinants for graft-versus-host disease after allogeneic haematopoietic stem cell transplantation.Int J Immunogenet. 2013 Dec;40(6):495-501. doi: 10.1111/iji.12051. Epub 2013 Mar 11.
24 Modeling Chronic Graft-versus-Host Disease in MHC-Matched Mouse Strains: Genetics, Graft Composition, and Tissue Targets.Biol Blood Marrow Transplant. 2019 Dec;25(12):2338-2349. doi: 10.1016/j.bbmt.2019.08.001. Epub 2019 Aug 12.
25 Clinical outcomes of HLA-DPB1 mismatches in 10/10 HLA-matched unrelated donor-recipient pairs undergoing allogeneic stem cell transplant.Eur J Haematol. 2017 Sep;99(3):275-282. doi: 10.1111/ejh.12916. Epub 2017 Jul 21.
26 Scleral lenses for severe chronic GvHD-related keratoconjunctivitis sicca: a retrospective study by the SFGM-TC.Bone Marrow Transplant. 2017 Jun;52(6):878-882. doi: 10.1038/bmt.2017.9. Epub 2017 Feb 20.
27 Biomarkers for acute and chronic graft-versus-host disease in regulatory T cells.Transpl Immunol. 2012 Dec;27(4):179-83. doi: 10.1016/j.trim.2012.07.003. Epub 2012 Aug 4.
28 Does minor histocompatibility antigen HA-1 disparity affect the occurrence of graft-versus-host disease in tunisian recipients of hematopoietic stem cells?.Clinics (Sao Paulo). 2010;65(11):1099-103. doi: 10.1590/s1807-59322010001100007.
29 Optimal dose of rabbit thymoglobulin in conditioning regimens for unmanipulated, haploidentical, hematopoietic stem cell transplantation: Long-term outcomes of a prospective randomized trial.Cancer. 2017 Aug 1;123(15):2881-2892. doi: 10.1002/cncr.30540. Epub 2017 Mar 16.
30 Trefoil factor expression in biliary epithelium of graft-versus-host disease of the liver after allogeneic hematopoietic cell transplantation.Transplantation. 2005 Oct 27;80(8):1099-104. doi: 10.1097/01.tp.0000179151.55881.a7.
31 Elevated level of HSPA1L mRNA correlates with graft-versus-host disease.Transpl Immunol. 2015 Jun;32(3):188-94. doi: 10.1016/j.trim.2015.02.002. Epub 2015 Feb 11.
32 Regulation of pulmonary graft-versus-host disease by IL-26+CD26+CD4 T lymphocytes.J Immunol. 2015 Apr 15;194(8):3697-712. doi: 10.4049/jimmunol.1402785. Epub 2015 Mar 18.
33 The Activating NKG2C Receptor Is Significantly Reduced in NK Cells after Allogeneic Stem Cell Transplantation in Patients with Severe Graft-versus-Host Disease.Int J Mol Sci. 2016 Oct 27;17(11):1797. doi: 10.3390/ijms17111797.
34 An alternative for extracorporeal photopheresis: 8-methoxypsoralen and UVA-treated leucocytes from allogeneic donors improve graft-versus-host disease in mice.Vox Sang. 2018 Nov;113(8):803-810. doi: 10.1111/vox.12723. Epub 2018 Oct 23.
35 Cardiomyopathy in murine models of systemic sclerosis.Arthritis Rheumatol. 2015 Feb;67(2):508-16. doi: 10.1002/art.38942.
36 Motor ability, function, and health-related quality of life as correlates of symptom burden in patients with sclerotic chronic graft-versus-host disease receiving imatinib mesylate.Support Care Cancer. 2020 Aug;28(8):3679-3689. doi: 10.1007/s00520-019-05207-z. Epub 2019 Dec 6.
37 Haploidentical vs. unrelated allogeneic stem cell transplantation for acute lymphoblastic leukemia in first complete remission: on behalf of the ALWP of the EBMT.Leukemia. 2020 Jan;34(1):283-292. doi: 10.1038/s41375-019-0544-3. Epub 2019 Aug 19.
38 Murine chronic graft-versus-host disease proteome profiling discovers CCL15 as a novel biomarker in patients.Blood. 2018 Apr 12;131(15):1743-1754. doi: 10.1182/blood-2017-08-800623. Epub 2018 Jan 18.
39 Association of autoimmune disease-related gene polymorphisms with chronic graft-versus-host disease.Br J Haematol. 2007 Nov;139(3):458-63. doi: 10.1111/j.1365-2141.2007.06797.x. Epub 2007 Sep 14.
40 The impact of HLA-E polymorphisms in graft-versus-host disease following HLA-E matched allogeneic hematopoietic stem cell transplantation.Iran J Allergy Asthma Immunol. 2012 Mar;11(1):15-21.
41 Donor-recipient combinations of group A and B KIR haplotypes and HLA class I ligand affect the outcome of HLA-matched, sibling donor hematopoietic cell transplantation.Hum Immunol. 2007 May;68(5):309-23. doi: 10.1016/j.humimm.2007.01.019. Epub 2007 Mar 12.
42 Matching for the nonconventional MHC-I MICA gene significantly reduces the incidence of acute and chronic GVHD.Blood. 2016 Oct 13;128(15):1979-1986. doi: 10.1182/blood-2016-05-719070. Epub 2016 Aug 22.
43 Fludarabine/busulfan versus fludarabine/total-body-irradiation (2Gy) as conditioning prior to allogeneic stem cell transplantation in patients (?0 years) with acute myelogenous leukemia: a study of the acute leukemia working party of the EBMT.Bone Marrow Transplant. 2020 Apr;55(4):729-739. doi: 10.1038/s41409-019-0720-0. Epub 2019 Oct 23.
44 Impaired bone marrow B-cell development in mice with a bronchiolitis obliterans model of cGVHD.Blood Adv. 2018 Sep 25;2(18):2307-2319. doi: 10.1182/bloodadvances.2017014977. Epub 2018 Sep 18.